Hennion & Walsh Asset Management Inc. increased its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI – Get Rating) by 65.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,408 shares of the company's stock after buying an additional 33,325 shares during the quarter. Hennion & Walsh Asset Management Inc.'s holdings in BeyondSpring were worth $186,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in shares of BeyondSpring during the 4th quarter worth $56,000. GSA Capital Partners LLP acquired a new position in BeyondSpring in the 4th quarter worth about $83,000. Alps Advisors Inc. acquired a new position in BeyondSpring in the 4th quarter worth about $205,000. Finally, BNP Paribas Arbitrage SA increased its holdings in BeyondSpring by 2,749.1% in the 4th quarter. BNP Paribas Arbitrage SA now owns 109,890 shares of the company's stock worth $498,000 after purchasing an additional 106,033 shares in the last quarter. 18.89% of the stock is currently owned by institutional investors.
Get BeyondSpring alerts:BeyondSpring Stock Up 1.3 %
Shares of BYSI opened at $1.60 on Friday. BeyondSpring Inc. has a 12-month low of $1.13 and a 12-month high of $33.00. The business has a 50-day simple moving average of $1.47 and a two-hundred day simple moving average of $2.28. The stock has a market cap of $62.29 million, a PE ratio of -0.98 and a beta of 1.10.
BeyondSpring (NASDAQ:BYSI – Get Rating) last issued its earnings results on Thursday, April 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. BeyondSpring had a negative return on equity of 144.52% and a negative net margin of 4,750.48%. The firm had revenue of $0.34 million during the quarter. On average, equities research analysts expect that BeyondSpring Inc. will post -0.95 EPS for the current year.BeyondSpring Profile
(Get Rating)
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
- MarketBeat: Week in Review 7/11 – 7/15
- Is Coupang's Stock On The Verge Of A Turnaround?
- Should You Have These Two Banks In Your Portfolio?
- Verint Systems Stock is a Customer Engagement Play
- Why Shopify Stock Split...And is as Shoppable as Ever
Want to see what other hedge funds are holding BYSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeyondSpring Inc. (NASDAQ:BYSI – Get Rating).
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.